The first thing I did when I saw that Eli Lilly had sued a med spa near where I grew up was go look at the page. It was gone. Whatever had been sitting on that service page when Lilly's counsel pulled its screenshots, someone had taken down.
So I did what anyone would do next, which was search the practice name with the drug, and there it was, sitting in the results. Search engines keep what websites lose. Then I ran the generic version of the search, med spa and retatrutide together, and that clinic came up first.
I think that is the entire story of how a four-location practice in the Sacramento suburbs ended up as one of six defendants named by one of the largest pharmaceutical companies in the world.
What Lilly filed
On August 12, Lilly filed six lawsuits over black-market retatrutide, the triple agonist it has in Phase 3 trials and expects to submit for FDA approval next year. Five of the six defendants are supply-side: a compounding pharmacy and four peptide sellers moving product under research-use labels. One is a clinic.
Every one of these is a false advertising claim under the Lanham Act, and that is not an accident. Private parties cannot sue under the Food, Drug and Cosmetic Act, so a drug company that wants to move against a seller in its own name has to find a theory that belongs to it. False advertising is that theory. Which means the case does not require proof that anyone was hurt, or that the vials were contaminated, or that a single patient complained. It requires advertising.
What Lilly is asking the court for is an injunction, a court order to stop, enforceable by contempt rather than by writing a check. Specifically, an order barring the clinic from marketing anything purporting to contain retatrutide, from citing Lilly's clinical trial data, and from implying the drug is FDA approved, plus corrective advertising and disgorgement of profits.
The evidence is thinner than you would expect
I have read a lot of these filings. Most of them are heavy with screenshots, secret shopper evidence, medical board complaints. This one is not.
Across twenty-three pages there are only four real images: two blocks of website copy, one Reddit post, and a set of Google reviews that do not actually reference reta. Everything else is a footnote pointing at a link that does not show what it supposedly once did.
And the images included are not what I would call solid evidence. There is no browser frame, no URL bar, no timestamp, no archive citation, nothing that fixes when or where the text was taken from. It is the copy, in the site's own typeface, floating in a box with a drop shadow. Which is roughly what you get when you copy what a search result shows you.
There is no test purchase either. No lab analysis of what is actually in the vials. No sales records, no patient records, no sign that anyone from Lilly or its firm walked into a single location.
It reads like it was built from public web pages, which is to say from roughly the same search I ran from my kitchen table.
That should not be reassuring. It is actually the opposite. The thin record is not a sign the case is weak, it is a measure of how little it took to bring one, and if the bar is that low for this practice, it is that low for everyone engaged in the same practice.
Why the claim works
The legal writing around this gets dense fast, so here is the plain version.
Lilly ran its trials on Lilly's retatrutide. Whatever a med spa is drawing into a syringe came from somewhere else entirely, most likely a supplier nobody has inspected, and it has never been studied by anyone. So when a clinic puts Lilly's trial numbers on a page selling its own product, it is making a promise about something no study has ever looked at.
The lie is not that retatrutide works. The lie is that this specific vial does what Lilly's research showed, when it is not a Lilly product.
That is why the quoted language in the complaint is what it is: the product described as a cutting-edge therapy and a next-generation treatment that may deliver up to 24% body weight reduction, the line telling consumers it outperforms semaglutide and tirzepatide in trials, the dosing page laying out a once-weekly injection titrated gradually, as though a validated protocol exists for a drug that has no approved protocol at all. Every sentence borrows credibility that belongs to somebody else's research.
Nowhere in the complaint is there an allegation about how much this practice sold, what it earned, or how many patients it treated. Lilly did not need any of that. It needed four sentences of website copy and strong language about patient safety.
| What the page claimed | Why it creates exposure |
|---|---|
| Cites Lilly Phase 3 percentages | Data describes Lilly's molecule, not the vial being sold |
| Compares favorably to semaglutide and tirzepatide | Head-to-head claim with no study behind the product sold |
| Publishes a weekly titration schedule | Implies an approved protocol where none exists |
| Frames the drug as a next-generation treatment | Suggests availability and approval status that is not real |
Why a small practice
There may be bigger operators doing exactly this with patient volumes this clinic will never see. But this lawsuit is not against a national chain or franchise, and I think that is kind of the point.
A four-location med spa cannot fight this. Litigation runs in stages, first motion practice where you argue the case should not proceed, then discovery where each side can compel documents, purchase records, and sworn testimony, and the fees start with your first response and never pause while you think. Most defendants never reach a courtroom. They settle, usually through a consent judgment, which means agreeing to have judgment entered against you on negotiated terms because continuing costs more than conceding.
And the insurance most practice owners assume will carry them probably will not. Professional liability responds to clinical negligence, not advertising claims. General liability may include advertising injury coverage, but those provisions routinely carve out false advertising about your own products, statements you had reason to know were false, and conduct involving a violation of law. A claim like this can land in all three exclusions at once. Practices tend to discover this after they are already defendants. If you have not read your own policy language on this, that is worth doing before anything else, and our malpractice and coverage primer is a reasonable place to start.
Then there is the part that ends the conversation. Lilly is asking the court to find the case exceptional under the Lanham Act so that it can recover its attorneys' fees, on top of the clinic's profits and its own costs. So the downside is your legal bills, possibly Lilly's counsel's legal bills, and repayment of everything you made on the product.
For Lilly, this is efficient. It gets a court order on the record and a public result, and it never finds out how a well-funded defendant would attack the soft spot in its theory, which is that Lilly does not sell retatrutide and has to establish that a med spa selling an unapproved molecule cost it sales of Mounjaro and Zepbound. A serious defendant would test that. A small clinic will settle first.
Lilly has said publicly that it has flagged more than fourteen thousand listings worldwide and referred more than two hundred individuals and entities to the FDA, the Department of Justice, state attorneys general, and licensing boards. Six lawsuits against fourteen thousand listings is not enforcement. It is a demonstration.
What I keep finding
I have kept running those searches since the filing, and every time I do, I find more of them. A practice with a retatrutide page. The same borrowed percentages. The same side-by-side against Mounjaro and Zepbound. Sometimes a dosing chart, which is the part that always stops me, because there is no approved dosing for this drug for anyone to be charting.
My honest instinct is to email these people, and I want to be careful about how that reads. I am not looking for a cleverer way to keep selling this, and I am not defending the practice that got sued. There is no compliant version of selling retatrutide right now. No approved formulation exists, no lawful commercial supply exists, and no amount of careful drafting puts a med spa on the right side of that. But more often than not, these clinics do not realize this is noncompliant. They see everyone else doing it, so why not them? You would be surprised how often I have to tell people that just because their competition is selling it does not make it right.
The big thing that put that clinic in front of Eli Lilly was its standard service page.
Why it is so easy to be noncompliant in a cash-pay practice
I do not think the people running these practices are more reckless than anyone else in medicine. I think they are working in the one corner of healthcare where almost nothing tells you no.
Everywhere else, the guardrails come attached to the money. In insurance-based medicine there is a formulary, prior authorization, payer policy, and a benefit manager who will simply decline to cover something. If you want to advertise a telehealth or pharmacy service on Google or Meta, you need LegitScript certification, and getting it means someone reviews what you actually do. If you are a digital health company selling to health plans, employers, or health systems, you are looking at SOC 2 and often HITRUST before anyone signs. Payment processors underwrite you. Credentialing bodies check you.
None of those exist to make you compliant. They exist to protect somebody else's money. But the effect is the same, because each one puts a stranger between you and getting paid, and that stranger asks questions before the revenue starts rather than after.
A cash-pay practice can skip nearly all of it. You need a website, a way to take a card, and patients who can find you. Nobody reviews your drug list, no claim gets denied, and if your traffic comes from organic search rather than paid ads, you never sit for the one review that would have caught this. That is worth sitting with, because the clinic Lilly sued ranked first for the obvious search without needing a single gatekeeper's approval to get there.
So the compliance function that other models get for free, as a side effect of who is paying, is a thing a cash-pay practice has to build on purpose or go without. Most go without, and they do not find out until something like this happens.
What happens to this practice now
I will be watching this one, and not for the reason you might think.
Their weight loss pages are down. When they came down, nobody outside this case can say. The footnotes state the site was last visited on August 6, six days before filing, but that is counsel's representation rather than proof, and nothing in the filing pins those text blocks to a live page on a given date. It is one of the things discovery would settle in about ten minutes.
What I can say is that taking the page down is not the remedy Lilly asked for. The injunction it wants goes considerably further than deletion: corrective advertising, disgorgement of profits, and a sworn report to the court detailing exactly how the clinic complied.
The likelier path from here is the quiet one. A practice this size does not litigate against Eli Lilly, so the case probably ends in a consent judgment within a few months, and whatever Lilly wants to know about where the product came from arrives as a settlement term rather than through a discovery fight.
How Camino helps
Most of the exposure in this story lives on marketing pages nobody treats as a regulated surface. We work with cash-pay practices, med spas, and telehealth operators to build the review layer their payment model never forced on them: a service and drug list someone actually signs off on, marketing claim review before copy ships, supplier and vendor due diligence, and documented ownership and oversight structures that match what the website says you do.
If you want a second set of eyes on your service pages and structure, tell us what you are building. If you are still sorting out entity and ownership rules by state, start with our state-by-state CPOM map and our earlier breakdown of the six Lilly filings.
Disclaimer
Camino Strategy Group is not a law firm or an accounting firm, and nothing here is legal, tax, or medical advice. This piece summarizes publicly reported filings and independent research as of the date published. The complaint described here contains allegations, not findings, and the clinic has not yet responded. Work with qualified counsel on your specific facts.
References
- Complaint, Eli Lilly and Company v. Aesthetic Envy Cosmetic Centers LLC, No. 2:26-cv-1347 (E.D. Cal. filed Aug. 12, 2026)
- Lilly, "Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market" (Aug. 12, 2026): https://www.prnewswire.com/news-releases/lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal-retatrutide-black-market-302849551.html
- CBS News, "Eli Lilly takes aim at illicit market for its experimental weight-loss drug" (Aug. 2026): https://www.cbsnews.com/news/eli-lilly-lawsuits-weight-loss-drug/
- BioPharma Dive, "Lilly files six lawsuits in bid to shut down 'black market' for retatrutide" (Aug. 12, 2026): https://www.biopharmadive.com/news/lilly-lawsuit-retatrutide-black-market-obesity-drug/827659/
- FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (June 15, 2026): https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- 15 U.S.C. 1125(a)(1)(B); 21 U.S.C. 355(i); 21 C.F.R. Part 312